The company has received a big blow from the Supreme Court. This company is Zydus Lifesciences Ltd. There is news that the Supreme Court has sent the company's case to the Delhi High Court. Let us tell you that interim relief has not been received from the SC in the breast cancer drug case. Delhi HC had banned the manufacturing and sale of Sigrima drug.

The Delhi High Court had issued an order to stop Zydus Lifesciences from selling its breast cancer drug Sigrima, which is a biosimilar to Roche's pertuzumab (brand name Perjeta).

The court's decision came in response to a patent infringement case filed by Swiss pharmaceutical company Roche against Zydus and Dr. Reddy's Laboratories. Both Dr. Reddy's and Zydus Lifesciences Ltd have jointly launched the drug. The company had told the exchange that it had tied up with Zydus to make this breast cancer drug available to patients in India. (Vodafone Idea Share: After the price halved in 3 months, now 70% growth is expected - report explains why there will be growth) HER2 positive breast cancer patients require a combination of trastuzumab and pertuzumab along with chemotherapy.  (Stock Crash: Biggest fall in stock – competition among sellers – lower circuit) We already offer biosimilar trastuzumab (Hervicta). With this product, we will be able to provide the full standard of care to HER2 positive breast cancer patients in India.